AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05287087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Symptoms 1 (MySt-1)
Description: The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2.
Study NCT05287087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Symptoms 2 (MySt-2)
Description: The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~5. Thorough symptom explanations~6. Physical energy (focus on sleep, diet and activity)~7. Values and choices (focus on meaning and existential issues)~8. Emotional health (focus on emotion regulation)~9. Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation.
Study NCT04556916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Per patient 49 ml of peripheral blood sample :~* 21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~* 28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation.
Study NCT04110132 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ganglion impar block with normal saline
Description: Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
Study NCT04441138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
Study NCT05018507 — intervention group
Intervention type: OTHER
Intervention: Data collection only
Description: No intervention, just data collection from system machines
Study NCT06346132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality application
Description: In this group, virtual reality will be added to usual care
Study NCT05462496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Pre-treatment tumor biopsy
Study NCT05462496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3
Study NCT05462496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
Study NCT05345860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for high risk or MRD+ TNBC patients
Description: Standard adjuvant chemotherapy + additional chemotherapy:~* BRCA positive patients: standard adjuvant chemotherapy + olaparib~* BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once.
Study NCT05345860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for high risk or MRD+ HER2+ patients
Description: Standard adjuvant chemotherapy + intensive targeted therapy:~* Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~* Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once.
Study NCT05345860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for high risk or MRD+ ER+ patients
Description: Standard adjuvant chemotherapy + intensive endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~* Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once.
Study NCT05345860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for low risk and MRD- TNBC patients
Description: Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice.
Study NCT05345860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for low risk and MRD- HER2+ patients
Description: Standard adjuvant chemotherapy + standard targeted therapy:~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~* Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice.
Study NCT05345860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for low risk and MRD- ER+ patients
Description: Standard adjuvant chemotherapy + standard endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~* Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice.
Study NCT04687995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic myringoplasty
Description: Endoscopic myringoplasty by using two different grafts one each time
Study NCT05363579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
Study NCT05363579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tuina therapy
Description: Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
Study NCT05363579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physio and Tuina therapy
Description: Physiotherapy mixed with Tuina
Study NCT04346563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape, functional correction technique
Description: According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.
Study NCT04346563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic band strengthening shoulder exercise
Description: The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week
Study NCT04346563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elastic band strengthening shoulder exercise
Description: The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week
Study NCT05462496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
Study NCT05462496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
Study NCT05462496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
Study NCT06397612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dose
Description: Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
Study NCT05513573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1500 mg, D1，Q3W
Study NCT05513573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: 300 mg, D1, up to 2 years,Q3W
Study NCT05513573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1500 mg, D1，Q3W
Study NCT05513573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
Study NCT04804345 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: retrospective study: standard of care
Study NCT05668624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean household energy
Description: LPG stoves/fuel for cooking and solar electricity for lighting
Study NCT05402072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous matrix-induced chondrogenesis (AMIC)
Description: AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
Study NCT05402072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous matrix-induced chondrogenesis (AMIC)
Description: AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
Study NCT05708508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROVALCYTE
Description: Immuno-guided strategy arm
Study NCT05708508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROVALCYTE
Description: Immuno-guided strategy arm
Study NCT05802134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable supplement
Description: Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
Study NCT05802134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and chronic disease management education
Description: Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
Study NCT05179577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: Arbaclofen Extended Release Tablets
Study NCT05179577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT04850963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (Anodal tDCS) + dual-task training
Description: anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session.
Study NCT04850963 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation (Anodal tDCS) + dual-task training
Description: anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session.
Study NCT04850963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS dualsite) + dual-task traning
Description: tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session.
Study NCT04850963 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS dualsite) + dual-task traning
Description: tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session.
Study NCT04850963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation sham + dual-task training
Description: tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session.
Study NCT05708690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
Study NCT05708690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
Study NCT05435209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Description: Gardasil
Study NCT06033612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV299
Description: Oral Suspension
Study NCT06033612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study NCT06033612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: pre-filled oral syringe
Study NCT05214365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation and conventional cardiac pacing
Description: Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
Study NCT05214365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conduction system pacing implant
Description: Right ventricular lead was placed to get his bundle or left bundle branch.